Cellosaurus logo
expasy logo
Due to maintenance work, this service will be unavailable from Mon Nov 11 17:30 until Tue Nov 12 09:00 CET. Apologies for the inconvenience.

Cellosaurus KU-19-19 (CVCL_1344)

[Text version]
Cell line name KU-19-19
Synonyms KU 19-19; KU19-19; KU1919; Keio University-19-19
Accession CVCL_1344
Resource Identification Initiative To cite this cell line use: KU-19-19 (RRID:CVCL_1344)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Japanese.
Doubling time: ~48 hours (DSMZ=ACC-395).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
Sequence variations
  • Mutation; HGNC; 391; AKT1; Simple; p.Glu17Lys (c.49G>A); ClinVar=VCV000013983; Zygosity=Unspecified (PubMed=19802009).
HLA typing Source: PubMed=26589293
Class I
HLA-AA*31:01,33:03
HLA-BB*15:01,37:01
HLA-CC*03:03,06:02
Genome ancestry Source: PubMed=30894373

Origin% genome
African0
Native American0
East Asian, North77.87
East Asian, South21.55
South Asian0
European, North0
European, South0.57
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling 76Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP=907312; DSMZ=ACC-395

Markers:
AmelogeninX
CSF1PO9,10
D2S133819
D3S135816,17
D5S81811,12
D7S82010,12
D8S117910,13
D13S31711
D16S53910,12
D18S5117,20
D19S43313,15
D21S1130,32
FGA22
Penta D13
Penta E10,15
TH017,8
TPOX8,11
vWA14,15

Run an STR similarity search on this cell line
Web pages http://www.cells-talk.com/index.php/page/copelibrary?key=KU-19-19
Publications

PubMed=7542171
Tachibana M., Miyakawa A., Tazaki H., Nakamura K., Kubo A., Hata J.-i., Nishi T., Amano Y.
Autocrine growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor.
Cancer Res. 55:3438-3443(1995)

PubMed=9464244; DOI=10.1006/bbrc.1997.8002
Steube K.G., Meyer C., Tachibana M., Murai M., Drexler H.G.
Bladder carcinoma cell line KU-19-19-derived cytokines support proliferation of growth factor-dependent hematopoietic cell lines: modulation by phorbol ester, interferon-gamma and interleukin-1 beta.
Biochem. Biophys. Res. Commun. 242:497-501(1998)

PubMed=10022529; DOI=10.1089/10430349950019174
Sumitomo M., Tachibana M., Ozu C., Asakura H., Murai M., Hayakawa M., Nakamura H., Takayanagi A., Shimizu N.
Induction of apoptosis of cytokine-producing bladder cancer cells by adenovirus-mediated IkappaBalpha overexpression.
Hum. Gene Ther. 10:37-47(1999)

PubMed=10496353; DOI=10.1038/sj.bjc.6690688; PMCID=PMC2362876
Sumitomo M., Tachibana M., Murai M., Hayakawa M., Nakamura H., Takayanagi A., Shimizu N.
Overexpression of IL-1ra gene up-regulates interleukin-1beta converting enzyme (ICE) gene expression: possible mechanism underlying IL-1beta-resistance of cancer cells.
Br. J. Cancer 81:277-286(1999)

PubMed=19802009; DOI=10.1038/onc.2009.315
Askham J.M., Platt F.M., Chambers P.A., Snowden H., Taylor C.F., Knowles M.A.
AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.
Oncogene 29:150-155(2010)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=24367658; DOI=10.1371/journal.pone.0084411; PMCID=PMC3867501
Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H., Knowles M.A.
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
PLoS ONE 8:E84411-E84411(2013)

PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057
Hurst C.D., Platt F.M., Knowles M.A.
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Eur. Urol. 65:367-369(2014)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) DSMZ; ACC-395
Cell line databases/resources CLO; CLO_0007123
cancercelllines; CVCL_1344
Cell_Model_Passport; SIDM01033
Cosmic-CLP; 907312
DepMap; ACH-000486
DSMZCellDive; ACC-395
LINCS_LDP; LCL-1715
Biological sample resources BioSample; SAMN03473576
BioSample; SAMN10988557
ENCODE; ENCBS304FRD
ENCODE; ENCBS497ZHB
CRISP screens repositories BioGRID_ORCS_Cell_line; 608
Chemistry resources ChEMBL-Cells; CHEMBL3308111
ChEMBL-Targets; CHEMBL1075483
GDSC; 907312
PharmacoDB; KU1919_794_2019
PubChem_Cell_line; CVCL_1344
Encyclopedic resources Wikidata; Q54900670
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM887243
GEO; GSM888317
GEO; GSM1374605
GEO; GSM1670010
Polymorphism and mutation databases Cosmic; 907312
Cosmic; 1046693
Cosmic; 1285122
Cosmic; 1286001
Cosmic; 2050448
Cosmic; 2057453
Cosmic; 2444234
Cosmic; 2686100
IARC_TP53; 21445
LiGeA; CCLE_760
Progenetix; CVCL_1344
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number40